| |
Article Title |
Author(s) |
Pages |
|
|
|
Introduction
As a result of global dietary changes and reduced physical activity, the world is currently faced with an epidemic of diabetes mellitus. The 25.8 million people with diabetes in the United States are ...
|
Michael H. Davidson,
Jorge Plutzky
|
1B-2B
|
|
|
|
Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose
Individuals with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are at high risk, not only to develop diabetes mellitus, but also to experience an adverse cardiovascular (CV) e...
|
Ralph A. DeFronzo,
Muhammad Abdul-Ghani
|
3B-24B
|
|
|
|
Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes
Type 2 diabetes has long been recognized as an independent risk factor for cardiovascular disease (CVD), including coronary artery disease (CAD), stroke, peripheral arterial disease, cardiomyopathy, a...
|
Jorge Plutzky
|
25B-32B
|
|
|
|
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
Type 2 diabetes mellitus is acknowledged as a major risk factor for the development of cardiovascular disease (CVD). Advancing treatment options for person with diabetes beyond glucose control to prev...
|
Michael H. Davidson
|
33B-41B
|
|
|
|
Implementing Cardiovascular Risk Reduction in Patients with Cardiovascular Disease and Diabetes Mellitus
The role of cardiovascular risk reduction in patients with diabetes mellitus is significant as several factors have been found to promote accelerated atherosclerosis in persons with diabetes including...
|
Shailesh Nandish,
Jamison Wyatt,
Oscar Bailon,
Mike Smith,
Rene Oliveros,
Robert Chilton
et al.
|
42B-51B
|
|
|
|
Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus
Research has substantiated that patients with type 2 diabetes mellitus are at increased risk for cardiovascular (CV) disease. It is well established that aggressive management of metabolic risk factor...
|
Vivian A. Fonseca
|
52B-58B
|
|
|
|
Emerging Therapeutic Approaches for the Management of Diabetes Mellitus and Macrovascular Complications
Type 2 diabetes mellitus (DM) affects an estimated 25.8 million people in the United States and is the 7th leading cause of death. While effective therapy can prevent or delay the complications that a...
|
Sherita Hill Golden
|
59B-67B
|
|
| Frontmatter |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Faculty List
The Cardiovascular Risk Continuum from Pre-Diabetes to Diabetes: The Role of the Cardiologist in Therapeutic Intervention to Alter the Disease Process
|
|
A4
|
|
|
|
Faculty Disclosures
The authors who contributed to this publication have disclosed the following industry relationships:
|
|
A5
|
|
